Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA)

被引：1
|
作者：
Ludwig, H. [1 ]
Crawford, J. [2 ]
Osterborg, A. [3 ]
Fleishman, A. [4 ]
Lillie, T. [4 ]
Sueto, T. [5 ]
Glaspy, J. [6 ]
机构：
[1] Wilhelminespital, Dept Med Oncol, Vienna, Austria
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] Amgen Inc, Thousand Oaks, CA USA
[5] Amgen GmbH, Int Med Affairs, Zug, Switzerland
[6] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70623-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1104
引用
收藏
页码：142 / 143
页数：2
相关论文
共 50 条
  • [21] Benefits From Antidepressants Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine
    Gibbons, Robert D.
    Hur, Kwan
    Brown, C. Hendricks
    Davis, John M.
    Mann, J. John
    ARCHIVES OF GENERAL PSYCHIATRY, 2012, 69 (06) : 572 - 579
  • [22] Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Smith, Robert E.
    Aapro, Matti S.
    Ludwig, Heinz
    Pinter, Tamas
    Smakal, Martin
    Ciuleanu, Tudor E.
    Chen, Li
    Lillie, Tom
    Glaspy, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1040 - 1050
  • [23] Correction of Anemia in the Frail Elderly (CAFE): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia
    Loaiza-Bonilla, Arturo
    Artz, Andrew
    Salerno, Francis
    Leng, Sean X.
    Yeh, Shing-Shing
    Biedenbender, Rex
    Gravenstein, Stefan
    Loera, Jose
    Geloo, Zeba Shaheen
    Ershler, William B.
    BLOOD, 2012, 120 (21)
  • [24] Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
    Hedenus, M
    Adriansson, M
    San Miguel, J
    Kramer, MHH
    Schipperus, MR
    Juvonen, E
    Taylor, K
    Belch, A
    Altés, A
    Martinelli, G
    Watson, D
    Matcham, J
    Rossi, G
    Littlewood, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) : 394 - 403
  • [25] Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy - Response
    Vansteenkiste, JF
    Colowick, AB
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) : 762 - 763
  • [26] Safety and efficacy of darbepoetin alfa treatment in anemic patients with symptomatic heart failure: a pooled analysis of two randomized, double-blind, placebo-controlled trials
    Abraham, W. T.
    Klapholz, M.
    Anand, I.
    Knusel, B.
    Rosser, D.
    Baker, N.
    Sun, Y.
    Van Veldhuisen, D. J.
    EUROPEAN HEART JOURNAL, 2006, 27 : 166 - 167
  • [27] FILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    MAHER, DW
    LIESCHKE, GJ
    GREEN, M
    BISHOP, J
    STUARTHARRIS, R
    WOLF, M
    SHERIDAN, WP
    KEFFORD, RF
    CEBON, J
    OLVER, I
    MCKENDRICK, J
    TONER, G
    BRADSTOCK, K
    LIESCHKE, M
    CRUICKSHANK, S
    TOMITA, DK
    HOFFMAN, EW
    FOX, RM
    MORSTYN, G
    ANNALS OF INTERNAL MEDICINE, 1994, 121 (07) : 492 - 501
  • [28] Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA).
    Vadhan-Raj, S
    Mirtsching, B
    Gregory, SA
    Hong, J
    Fessen, M
    Yao, B
    Rossi, G
    Blayney, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 744S - 744S
  • [29] Evaluation of extended dosing intervals versus weekly dosing of darbepoetin alfa (DA): A phase 2 study in cancer patients (pts) with chemotherapy-induced anemia (CIA)
    Rearden, T.
    Schwartzberg, L.
    Mirtsching, B.
    Tomita, D.
    Lillie, T.
    Burkes, R.
    Silberstein, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 154 - 154
  • [30] Changes in iron parameters in patients (pts) with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa (DA) every 3 weeks with and without intravenous iron supplementation
    Suto, T.
    Vansteenkiste, J. F.
    Mossman, T.
    Pinter, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345